Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Evercore's DiFiore on Amylyx Pharmaceuticals inc. (AMLX) ALS Relyvrio Launch: 'I feel very confident in launch and remain very constructive'
February 9, 2023 12:16 PM ESTEvercore ISI analyst Umer Raffat reiterated an Outperform rating and {REMOVEPT} price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX).
The analyst comments "I disagree with Street buzz & Cigna decision contradicts itself There is a ton of confusion in the marketplace on Amylyx... More
